RE: hope17 Sep 2020 09:52
Morning The.Italian.
We don't actually have nothing and I am pretty sure this wont fall off a cliff since we are coming close to the FDA phase 3 and possible license agreement and EU OTC launch. Currently the sp is again being driven by small traders, with the occasional large holder taking the recent volume increase to build a position (remember the 2,3,4 and 5mill buys recently.
If you remember at the time of the Yooya fiasco the offer was at 0.25, we are currently at 0.16 or there abouts, so I cannot see it dropping below the low level after the failure. But given that they are giving away 23% (dilution) of the company for an unprecedented 0.067 I would expect the SP would more than likely fall to around 0.05 or less in the short term to compensate for the new share volume. Particularly since they appear to have nothing to offer in the short to medium term. So I feel the SP and the companies finances would be much better off without it. Just my opinion based on historic events. Also note that the loss at the end of this year will now also include paying all their staff and for their own R&D, which wont just be a paper exercise but an actual loss).
Unless they have something going on in the background re Fortacin, which could change this and would be an entirely different story. but we don't know that. We only know we will be carrying just more parasitic luggage.